Orchid Chemicals & Pharmaceuticals Ltd. May 2 announced that the Food and Drug Administration has approved its abbreviated new drug application for naratriptan tablets in the 1 mg and 2.5 mg strengths.
Naratriptan is the generic equivalent of GlaxoSmithKline’s Amerge, the Chennai, India-based company said.
Amerge is indicated for the acute treatment of migraine attacks with or without aura in adults, according to GlaxoSmithKline’s website.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.